Nasodine trial in COVID-19 started

  26 Apr 2022

Firebrick Pharma is pleased to announce that the Phase 2 COVID-19 clinical trial for Nasodine® Nasal Spray (“Nasodine”) in South Africa has commenced, with the first patient now recruited. 

Read More